## Parenteral Manufacturing

Experts in development and manufacture of parenteral products Alcami's 4,460 square meter manufacturing facility in Charleston, South Carolina, is home to a scientific and technical staff with extensive experience in supporting programs from preclinical all the way through to commercial supply. This US- and EU- compliant and DEA-licensed manufacturing facility is fully integrated with packaging and distribution and benefits from world-class analytical support - especially important when working with complex large molecules, and addressing the challenges surrounding extractables and leachables. Alcami routinely works with small molecules, and a wide range of biologics (proteins, peptides, monoclonal antibodies).


Manufacturing Capabilities:

- Aseptic vial filling
- Terminally sterilization
- Sterile solutions, suspensions, emulsions
- Lyophilization cycle development
- Batch size from 200 mL up to 340 L
- 2 ml to 50 ml vials
- Class 100 capping
.2 ml to 50 ml vials, few hundred to 30,000 vials
- Process Development, Optimization and Validation through regular commercial manufacture
- Solutions, Emulsions, Suspensions,

Homogenization 5 sq m lyophilizer, 3 ml to 50 ml vials

- Liquid Fills of Solvent-based Formulations
- DEA-compliant for Schedule II-IV Compounds
- Visual Inspections
- Automated Filling
- Isolation Capabilities for Potent Compounds



## Alcami Advantage

Alcami provides custom packaging, labeling and kitting for materials destined for trials anywhere in the world. We also provide specialized expert support for randomization and blinding studies, including placebo, comparator and crossover studies, as well as reconciliation drug accountability and destruction service as needed.

Charleston, South Carolina

Liquid Fills of Solvent-Based Formulations $2 \mathrm{~mL}-50 \mathrm{~mL}$ vials Batch Size 100-30,000 vials

Solutions, Emulsions,
Suspensions and Homogenization (including Micro fluidization Capacity 25 - 150L)

Lyophilized Formulations


Pre-Filled Syringes (Coming
Soon)

